Schedule a Meeting
Get a SampleFebruary 2025
The global gene therapy market size is calculated at USD 11.07 billion in 2025 and is forecasted to reach around USD 55.43 billion by 2034, accelerating at a CAGR of 19.60% from 2025 to 2034. The North America gene therapy market size surpassed USD 5 billion in 2024 and is expanding at a CAGR of 19.62% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
The global gene therapy market size accounted for USD 9.26 billion in 2024, grew to USD 11.07 billion in 2025 and is expected to be worth around USD 55.43 billion by 2034, registering a healthy CAGR of 19.60% between 2024 and 2034.
The U.S. gene therapy market reached USD 3.63 billion in 2024 and is predicted to grow around USD 22.08 billion by 2034, poised to grow at a registered CAGR of 19.79% from 2025 to 2034.
The North America segment dominated the global gene therapy market in 2024, in terms of revenue and is estimated to sustain its dominance during the forecast period. The several government organizations are supporting research campaigns around the country, owing to the robust regulatory framework for cellular treatment development and the substantial presence of biopharmaceutical businesses.
Europe is estimated to be the most opportunistic segment during the forecast period. The presence of modern healthcare infrastructure, availability of reimbursements, and the presence of significant industry players in the region are all major factors driving the growth of the gene therapy market in the Europe.
The gene therapy is described as the treatment of an illness by changing, replacing, or supplementing a missing or defective genetic combination that is responsible for the disease. The gene therapy has become one of the most desirable research goals in the fight against degenerative illnesses. The need for gene therapy is being driven by an increase in the number of cases of cancer and other chronic diseases all across the world. The advancements in gene therapies are projected to be approved in the upcoming years, contributing to the gene therapy market’s growth during the forecast period.
The gene therapies are designed to treat diseases by altering genetic information, such as inactivating malfunctioning genes or replacing a disease-causing gene with a healthy copy of gene. The gene therapy is being utilized to treat a variety of disorders and has demonstrated to be effective. This form of treatment can cure diseases such as diabetes, cancer, heart disease, and AIDS.
The growth of the gene therapy market is influenced by factors such as a strong product portfolio, the expanding investments by key market players, and a high prevalence of target diseases and interest in innovative and new therapy. Nonetheless, the high cost of product development and strict management tactics are expected to hinder the growth of gene therapy market.
Furthermore, the increased investment in research and development by government and private organizations will create further prospects for the growth of gene therapy market during the forecast period. However, the severe side effects such as poor immune responses could stymie the gene therapy market’s expansion in the near future.
The advanced therapeutic solutions for chronic diseases are being used in developed countries. As a result, traditional treatment methods like as chemotherapy, which have adverse side effects and long-term repercussions, are being replaced with this treatment. For the development of such medicines, there is also a shift in trend towards the use of viral vectors, which have a low toxicity and high immunology.
The rapid technological advancements in cellular and molecular biology in genomics research, have contributed greatly to the growing gene therapy market in recent years. The academicians, researchers, and in-house researchers of major market companies with significant funding have all played critical roles.
In many industrialized countries, the frequency of cardiovascular diseases is increasing, and there is a growing need to cure these diseases in less time, resulting in players investing extensively in research and development of highly effective and innovative therapeutics such as gene therapy. The prevalence of rare diseases such as cardiovascular and cancer diseases will have positive impact on the demand for gene therapy applications.
Currently, only a few market players are dominating the gene therapy market. These market players are significantly contributing to the market’s expansion. The core members who are working on item dispatching and other important coordinated activities to strengthen their market reach globally. To increase their cancer gene therapy research and product portfolio, local and small market players are increasingly partnering and developing alliances with large market players.
| Report Coverage | Details |
| Market Size in 2024 | USD 9.26 Billion |
| Market Size by 2034 | USD 55.43 Billion |
| Growth Rate from 2025 to 2034 | CAGR of 19.60% |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2024 |
| Forecast Period | 2024 to 2034 |
| Segments Covered | Type, Vector, Therapeutic Area, Delivery Method, Route of Administration and Region |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
The gene silencing segment dominated the gene therapy market with the largest share in 2024 owing to its high accuracy. The gene silencing mechanism enables precise targeting of specific genes that are responsible for diseases. This targeted approach reduces the expression of harmful genes, making it ideal for treating various diseases, such as cancers, genetic disorders, and viral infections. Furthermore, gene silencing is increasingly being used to produce therapeutics for cancer and other diseases.
The viral vector segment held around 85% share of the market in 2024 due to its capability to target specific cells with precision. Viral vectors have high transduction rates, making them suitable for transferring genes into targeted cells. The increase in demand for targeted delivery systems further bolstered the segment. In addition, they are effective at delivering genetic materials into host cells, making them suitable for gene therapy.
The non-viral vector segment is expected to be the most opportunistic segment during the forecast period. This is due to the widespread availability of non-viral vector gene treatments. In gene therapy, non-viral vectors are highly preferred over viral vectors due to their ease of production and better safety profile. Moreover, they reduce the risk of insertional mutagenesis, making them a safer option for patients.
The oncology segment dominated the global gene therapy market in 2024. This is mainly due to the rise in the prevalence of cancer across the globe. Gene therapies have gained immense traction to treat cancer due to their ability to target specific cancer cells. Moreover, gene therapies have fewer side effects than chemotherapy, making them a preferable choice. The rise in approval of gene therapies for cancer and incidence of hematologic tumors further bolstered the segment.
The neurology segment is expected to grow rapidly during the forecast period. This is mainly due to the increasing occurrence of neurological diseases, such as Alzheimer’s and Parkinson’s. According to the Alzheimer’s Association,Alzheimer's disease was the fifth-leading cause of death in 2021. About 7 million people in the U.S. are living with Alzheimer's, and this number is projected to reach nearly 13 million by 2050. Targeted gene therapy has advanced significantly, allowing for the treatment of neurological illnesses using various techniques, ranging from exogenous gene expression to endogenous gene suppression.
The in vivo segment registered its dominance in the gene therapy market in 2024. The segment growth is attributed to the fact that the in vivo method delivers genes directly into the patient’s body, enhancing the effectiveness of the treatment. This method is less invasive and eliminates the need for complex procedures, including ex vivo. With the increased demand for targeted therapies, in vivo gene therapy gained immense popularity, propelling the segment.
The intravenous segment led the market in 2024. This is mainly due to the ability of intravenous (IV) administration to deliver treatments directly into the bloodstream of the patient. This method is used to treat various conditions due to its ability to deliver gene therapy to multiple targeted organs simultaneously. Moreover, the faster delivery to targeted tissues and high effectiveness bolstered the segment. Advancements in vector design and delivery mechanisms led to the development of minimally invasive IV therapy, contributing to segmental growth.
The key market players can expect profitable growth possibilities as research and development investments are rising at a rapid pace. In addition, the market players are implementing key marketing strategies for the growth and development of gene therapy market. REGENXBIO Inc. and Ultragenyx Pharmaceutical Inc., for example, deployed new technology for the development of gene therapy treatments in March 2020.
By Type
By Vector
By Therapeutic Area
By Delivery Method
By Route of Administration
By Geography
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
February 2025
January 2025
November 2024
November 2024